GCM
VRDN icon

Graham Capital Management’s Viridian Therapeutics VRDN Stock Holding History

Graham Capital Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$362K Sell
18,485
-6,344
-26% -$188K 0.01% 739
2025
Q4 		$773K Sell
24,829
-12,661
-34% -$347K 0.02% 463
2025
Q3 		$809K Sell
37,490
-17,706
-32% -$319K 0.01% 447
2025
Q2 		$772K Buy
55,196
+37,013
+204% +$502K 0.01% 668
2025
Q1 		$245K Buy
18,183
+5,283
+41% +$90K ﹤0.01% 1066
2024
Q4 		$247K Sell
12,900
-1,533
-11% -$33.3K ﹤0.01% 1009
2024
Q3 		$328K Sell
14,433
-8,011
-36% -$131K 0.01% 751
2024
Q2 		$292K Buy
+22,444
New +$311K 0.01% 745

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return